HKG:0013

2 stories mentioning HKG:0013Updated 34d ago

Every FINWIRES story that references HKG:0013, newest first.

Innovent Biologics, Hutchmed's Drug Combination Application to Treat Renal Cell Carcinoma Gets China Nod

Innovent Biologics (HKG:1801) and Hutchmed (China) (HKG:0013) obtained approval for a new drug application for the combination of TYVYT and ELUNATE from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The combination is intended to treat patients with locally advanced or metastatic renal cell carcinoma.Hutchmed co-developed ELUNATE with Eli Lilly and Company, while TYVYT was co-developed by Innovent Biologics and Eli Lilly.

HKG:0013HKG:1801

Asia56d ago

Hutchmed's Application for Immune Disease Drug Accepted, Granted Priority Review in China

Hutchmed (China)'s (HKG:0013) new drug application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia has been accepted for review and granted priority review by China's National Medical Products Administration.Sovleplenib is being developed for the treatment of immune diseases and hematological malignancies, according to a Wednesday Hong Kong bourse filing.

HKG:0013

Track with the FINWIRES app suite

FolioX

Track HKG:0013 in your portfolio

WheelAI

Analyze HKG:0013 options with the wheel strategy

StockInsider

See market sentiment on HKG:0013